Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 13.69%.

  • Indivior Pharmaceuticals' EBIT Margin rose 22900.0% to 13.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.24%, marking a year-over-year increase of 156900.0%. This contributed to the annual value of 3.2% for FY2024, which is 35600.0% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its EBIT Margin stood at 13.69% for Q3 2025, which was up 22900.0% from 23.84% recorded in Q2 2025.
  • Indivior Pharmaceuticals' EBIT Margin's 5-year high stood at 28.51% during Q2 2022, with a 5-year trough of 107.05% in Q4 2022.
  • For the 4-year period, Indivior Pharmaceuticals' EBIT Margin averaged around 1.13%, with its median value being 21.29% (2023).
  • Over the last 5 years, Indivior Pharmaceuticals' EBIT Margin had its largest YoY gain of 1275300bps in 2023, and its largest YoY loss of -916700bps in 2023.
  • Over the past 4 years, Indivior Pharmaceuticals' EBIT Margin (Quarter) stood at 107.05% in 2022, then skyrocketed by 119bps to 20.48% in 2023, then decreased by -25bps to 15.44% in 2024, then dropped by -11bps to 13.69% in 2025.
  • Its EBIT Margin stands at 13.69% for Q3 2025, versus 23.84% for Q2 2025 and 24.81% for Q1 2025.